This session covers the latest clinical and translational evidence on lung transplant outcomes. National and institutional data will be presented on induction strategies and outcomes for redo lung transplant. An important highlight will be the presentation of international data from ECLS registry. Since use of extracorporeal support during lung transplant remains a topic of controversy, this session will highlight both sides of the argument.

*Unless otherwise noted, speakers have nothing to disclose.

Moderators

Gita Mody

Digital Moderators

Joshua Sonett (Commercial Relationships: Ethicon: Consultant Advisory/Board; Medtronic, Consultant Advisory/Board)

Presentations:

1. Outcomes of Lung Transplantation from HCV Viremic Donors in the Era of Direct-Acting Antiviral Therapy - Selena Li

2. Assessing Donor Organ Quality by Recipient Characteristics in Lung Transplantation - Benjamin Wadowski

3. Impact of Total Time of Intraoperative Extracorporeal Life Support (ECLS) on Outcomes After Bilateral Lung Transplantation (LTx): Update From The International Multicenter ECLS in LTx Registry - Matthew Hartwig

(Commercial Relationships: Biomedinnovations, Consultant Advisory/Board; Intuitive Surgical, Research Grant, Grant Research Support; Mallickrodt Pharmaceuticals, Research Grant; Paragonix, Consultant Advisory/Board)

4. Induction Therapy in Lung Transplantation: A Contemporary Analysis of Trends and Outcomes - Larisa Shagabayeva

5. Analysis of outcomes after lung re-transplantation suggests preferred care pathways for patients - Simran Randhawa

6. Panel Discussion

7. Debate: Lung transplant should be performed without extracorporeal support - Usman Ahmad

8. Debate: Routine use of extracorporeal support should be the standard for lung transplant - Konrad Hoetzenecker

9. Panel Discussion